The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00599092
Recruitment Status : **RECRUITING NOW**
First Posted : January 23, 2008
Last Update Posted : February 8, 2023
Sponsor:
Information provided by (Responsible Party):
Shlomo Melmed, MD, Cedars-Sinai Medical Center
Go toÂ
Brief Summary:
The purpose of this study is to observe predictors of pituitary tumor recurrence and markers of persistent disease activity in patients harboring pituitary mass lesions of all types.
Pituitary Tumor
Detailed Description:
The purpose of this study is to observe predictors of pituitary tumor recurrence and markers of persistent disease activity through computerized collection of comprehensive demographic, therapeutic, pathologic and outcome information on patients harboring pituitary mass lesions of all types.
Go toÂ
Layout table for study information
Study Type :
Observational
Estimated Enrollment :
1250 participants
Observational Model:
Other
Time Perspective:
Prospective
Official Title:
Pituitary Tumor Surveillance: Pathogenetic Correlation
Study Start Date :
January 1997
Estimated Primary Completion Date :
December 2050
Estimated Study Completion Date :
December 2050
Resource links provided by the National Library of Medicine
Go toÂ
Go toÂ
Biospecimen Retention: Â Samples With DNAwhole blood
Go toÂ
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study: Â
18 Years and older  (Adult, Older Adult)
Sexes Eligible for Study: Â
All
Accepts Healthy Volunteers: Â
Yes
Sampling Method: Â
Non-Probability Sample
tertiary referral center
Inclusion Criteria:
patients with confirmed pituitary disease
Exclusion Criteria:
patients who do not have confirmed pituitary disease
Go toÂ
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00599092
Layout table for location information
Cedars-Sinai Medical Center, Pituitary Center
Los Angeles, California, United States, 90048
Contact: Daniel Akers   310-423-3395   daniel.akers@cshs.org  Â
Contact: Lori Korsakoff, RN   310-423-2411   lori.korsakoff@cshs.org  Â
Principal Investigator: Shlomo Melmed, MD Â Â Â Â Â Â
Cedars-Sinai Medical Center
Layout table for investigator information
Principal Investigator:
Shlomo Melmed, MD
Cedars-Sinai Medical Center, Pituitary Center
Go toÂ
Layout table for additonal information
Responsible Party:
Shlomo Melmed, MD, Professor of Medicine, Cedars-Sinai Medical Center
ClinicalTrials.gov Identifier:
NCT00599092 Â Â
Other Study ID Numbers:
28732873
First Posted:
January 23, 2008 Â Â Key Record Dates
Last Update Posted:
February 8, 2023
Last Verified:
August 2021
Keywords provided by Shlomo Melmed, MD, Cedars-Sinai Medical Center:
pituitary tumorrecurrence
Additional relevant MeSH terms:
Layout table for MeSH terms
Pituitary NeoplasmsPituitary DiseasesNeoplasmsHypothalamic DiseasesBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesEndocrine System Diseases
Endocrine Gland NeoplasmsNeoplasms by SiteHypothalamic NeoplasmsSupratentorial NeoplasmsBrain NeoplasmsCentral Nervous System NeoplasmsNervous System Neoplasms
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
